MDWD MediWound Limited

MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that 6 presentations highlighting the positive results achieved by clinicians using NexoBrid® as an effective enzymatic debridement for severe burns and EscharEx for debridement of chronic wounds, will be presented during the American Burn Association (ABA) 49th Annual Meeting, taking place March 21-24, 2017 at the Hynes Convention Center in Boston, Massachusetts. 

“We are delighted that burn and wound specialists continue to share their positive hands-on experience with NexoBrid and EscharEx at the ABA meeting before a global audience of their peers. The growing body of real-world clinical evidence demonstrating the effective enzymatic debridement of NexoBrid and EscharEx enhances awareness of their clinical and pharmaco-economic benefits and underscores the important role these proteolytic enzymes can play in the treatment of severe burns and chronic wounds,” said Gal Cohen, President and Chief Executive Officer of MediWound.

“To date, there have been hundreds of posters and presentations by burn and wound specialists extolling the virtues of NexoBrid and EscharEx in burn and wound care, respectively.  We continue to appreciate the increasing number of investigator-led studies by burn and wound care specialists as they provide the data to support the use of these products in a variety of severe burns and chronic wounds and, importantly, they foster peer-to-peer discussions that can enhance product adoption,” added Mr. Cohen.  

The following data highlighting NexoBrid and EscharEx will be presented during the ABA meeting: 

Title:						“Wound Bed Assessment After Enzymatic Eschar Removal: To Operate or Not to Operate?
Poster						Oral Presentation #71
Author:						S. Monstrey, MD, PhD, Ghent University Hospital, Ghent, Belgium
Date/Time:						March 23rd from 10:00 a.m. – 12:00 p.m.
Location:						Independence Ballroom
Title:						“Challenging the 21 Day Golden Rule for Wound Closure: Lessons Learned from Rapid Enzymatic Eschar Removal in Deep Burns Assessed by LDI”
Poster:						Oral Presentation #113
Author:						Henk Hoeksema, PT, Department of Plastic and Reconstructive Surgery – Burn Centre, Ghent University Hospital
Date/Time:						March 24th from 10:00 a.m. – 12:00 p.m.
Location:						Independence Ballroom
Title:						“The Role of Rapid Enzymatic Debridement in Burn Mass Casualty Incidents: Lessons Learned from Ground Breaking Experience in the 2015 Bucharest Nightclub Fire”
Poster:						Poster presentation #207
Author:						Ilaria Mataro, MD, Department of Plastic and Reconstructive Surgery, Cardarelli Hospital, Naples, Italy
Date/Time:						March 22nd from 12:30 p.m. – 1:45p.m.
Location:						Hynes Convention Hall D
Title:						“Bromelain Based Enzymatic Debridement of Chronic Wounds: Results of a Multicenter Phase II Trial”
Poster:						Poster presentation #248
Author:						Y. Shoham, MD, Soroka University Medical Center, Beer Sheva, Israel;
Date/Time:						March 23rd from 12:30 p.m. – 1:45p.m.
Location:						Hynes Convention Hall D
Title:						“Faster Wound Healing of Enzymatically Debrided Deep Dermal Burns by Using Sprayed Autologous Keratinocytes”
Poster:						Poster presentation #250
Author:						Frank Sander, M.D., Specialist in Plastic and Aesthetic Surgery, Trauma Hospital Berlin, Berlin, Germany
Date/Time:						March 23rd from 12:30 p.m. – 1:45p.m.
Location:						Hynes Convention Hall D
.
Title:						“Functional Outcomes after Enzymatic Debridement of Hand Burns”
Poster:						Poster presentation #251
Authors:						Jose Ramon Martinez-Mendez, M.D., Plastic Surgery, Hospital Universitario La Paz, Madrid, Spain
Date/Time:						March 23rd from 12:30 p.m. – 1:45p.m.
Location:						Hynes Convention Hall D

About the American Burn Association

The American Burn Association and its members dedicate their efforts and resources to promoting and supporting burn-related research, education, care, rehabilitation, and prevention. The ABA has more than 3,500 members in the United States, Canada, Europe, Asia, and Latin America. Members include physicians, nurses, occupational and physical therapists, researchers, social workers, firefighters, and hospitals with burn centers. The ABA’s multidisciplinary membership enhances its ability to work toward common goals with other organizations on educational programs.

About MediWound Ltd.

MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe and Israel, with plans for a launch in Argentina. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues.

MediWound's second innovative product, EscharEx® is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx® contains the same proteolytic enzyme technology as NexoBrid®, and benefits from the wealth of existing development data on NexoBrid®.  In two Phase 2 studies, EscharEx® has demonstrated safety and efficacy in the debridement of chronic and other hard-to-heal wounds, within a few daily applications.   For more information, please visit www.mediwound.com. 

Cautionary Note Regarding Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to the regulatory authorizations and launch dates. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on MediWound’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. In particular, you should consider the risks discussed under the heading “Risk Factors” in our annual report on Form 20-F for the year ended December 31, 2016 and information contained in other documents filed with or furnished to the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The forward-looking statements made herein speak only as of the date of this announcement and MediWound undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Contacts:
Sharon Malka
Chief Financial and Operations Officer
MediWound
ir@mediwound.co.il

Anne Marie Fields
Senior Vice President
LHA
212-838-3777
afields@lhai.com